Amylyx Pharmaceuticals Long Term Debt

Amylyx Pharmaceuticals's long-term debt stands at $4.5M as of March 2026. That compares with $330K in the prior-year period — up 1268.8% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Amylyx Pharmaceuticals reported $4.5M in long-term debt versus $330K a year earlier — a 1268.8% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $330K in the prior-year period — up 1268.8% year over year. Sustained growth in long-term debt can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Amylyx Pharmaceuticals's long-term debt evolved across reporting periods, while the comparison chart places AMLX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.